Further to Sareum’s announcement on 27 October 2020, it has today confirmed that the formal Grant Offer Letter from UK Research & Innovation (UKRI) has been approved. This confirms Sareum’s successful application for approximately £174,000 in grant funding to investigate the therapeutic potential of SDC-1801, its selective, small molecule TYK2/JAK1 kinase inhibitor, in severe phase Covid-19.
